The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
A Novel FMR1 PCR Method for the Routine Detection of Low Abundance Expanded Alleles and Full Mutations in Fragile X Syndrome
Open accessAbstract
Background: Fragile X syndrome (FXS) is a trinucleotide-repeat disease caused by the expansion of CGG sequences in the 5′ untranslated region of the FMR1 (fragile X mental retardation 1) gene. Molecular diagnoses of FXS and other emerging FMR1 disorders typically rely on 2 tests, PCR and Southern blotting; however, performance or throughput limitations of these methods currently constrain routine testing. Methods: We evaluated a novel FMR1 gene–specific PCR technology with DNA templates from 20 cell lines and 146 blinded clinical samples. The CGG repeat number was determined by fragment sizing of PCR amplicons with capillary electrophoresis, and results were compared with those for FMR1 Southern blotting analyses with the same samples. Results: The FMR1 PCR accurately detected full-mutation alleles up to at least 1300 CGG repeats and consisting of >99% GC character. All categories of alleles detected by Southern blotting, including 66 samples with full mutations, were also identified by the FMR1 PCR for each of the 146 clinical samples. Because all full mutation alleles in samples from heterozygous females were detected by the PCR, allele zygosity was reconciled in every case. The PCR reagents also detected a 1% mass fraction of a 940-CGG allele in a background of 99% 23-CGG allele—a roughly 5- fold greater sensitivity than obtained with Southern blotting. Conclusions: The novel PCR technology can accurately categorize the spectrum of FMR1 alleles, including alleles previously considered too large to amplify; reproducibly detect low abundance full mutation alleles; and correctly infer homozygosity in female samples, thus greatly reducing the need for sample reflexing to Southern blotting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Pieretti, M., Sutcliffe, J. S., Richards, S., Verkert, A. J. M. H., Holden, J. J. A., Fenwick, R. G., Warren, S. T., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90283-5 · Cited by 2,080
Instability of a 550-Base Pair DNA Segment and Abnormal Methylation in Fragile X Syndrome
Oberlé, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A., Boué, J., Bertheas, M. F., & Mandel, J. L. (1991) · Science · doi:10.1126/science.252.5009.1097 · Cited by 1,499
Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X
Hagerman, R. J., Leehey, M., Heinrichs, W., Tassone, F., Wilson, R., Hills, J., Grigsby, J., Gage, B., & Hagerman, P. J. (2001) · Neurology · doi:10.1212/wnl.57.1.127 · Cited by 964
Self-citationAllingham-Hawkins, D. J., Babul-Hirji, R., Chitayat, D., Holden, J. J. A., Yang, K. T., Lee, C., Hudson, R., Gorwill, H., Nolin, S. L., Glicksman, A., et al. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990402)83:4<322::aid-ajmg17>3.0.co;2-b · Cited by 502
Fragile X Syndrome: Diagnosis, Treatment, And Research
Silverman, & Cronister, A. (1991) · Johns Hopkins University Press eBooks · Cited by 481
Tassone, F., Pan, R., Amiri, K., Taylor, A. K., & Hagerman, P. J. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070073 · Cited by 350
Self-citationFragile X syndrome: Diagnostic and carrier testing
Sherman, S., Pletcher, B. A., & Driscoll, D. A. (2005) · Genetics in Medicine · doi:10.1097/01.gim.0000182468.22666.dd · Cited by 277
The fragile X premutation: into the phenotypic fold
Hagerman, R. J., & Hagerman, P. J. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00299-x · Cited by 259
Self-citationMaddalena, A., Richards, C. S., McGinniss, M. J., Brothman, A., Desnick, R. J., Grier, R. E., Hirsch, B., Jacky, P., McDowell, G. A., Popovich, B., et al. (2001) · Genetics in Medicine · doi:10.1097/00125817-200105000-00010 · Cited by 231
Cited by
Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics
Bagni, C., Tassone, F., Neri, G., & Hagerman, R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63141 · Cited by 321
Self-citationFMR1 CGG allele size and prevalence ascertained through newborn screening in the United States
Tassone, F., Iong, K. P., Tong, T.-H., Lo, J., Gane, L. W., Berry-Kravis, E., Nguyen, D., Mu, L. Y., Laffin, J., Bailey, D. B., et al. (2012) · Genome Medicine · doi:10.1186/gm401 · Cited by 315
Self-citationAltered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome
Hoeffer, C. A., Sanchez, E., Hagerman, R. J., Mu, Y., Nguyen, D. V., Wong, H., Whelan, A. M., Zukin, R. S., Klann, E., & Tassone, F. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00768.x · Cited by 198
Self-citationAGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome
Yrigollen, C. M., Durbin-Johnson, B., Gane, L., Nelson, D. L., Hagerman, R., Hagerman, P. J., & Tassone, F. (2012) · Genetics in Medicine · doi:10.1038/gim.2012.34 · Cited by 179
Self-citationBrain Transcriptional and Epigenetic Associations with Autism
Ginsberg, M. R., Rubin, R. A., Falcone, T., Ting, A. H., & Natowicz, M. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044736 · Cited by 164
Fragile X syndrome: a review of clinical and molecular diagnoses
Ciaccio, C., Fontana, L., Milani, D., Tabano, S., Miozzo, M., & Esposito, S. (2017) · Italian Journal of Pediatrics · doi:10.1186/s13052-017-0355-y · Cited by 160
High MMP-9 activity levels in fragile X syndrome are lowered by minocycline
Dziembowska, M., Pretto, D. I., Janusz, A., Kaczmarek, L., Leigh, M. J., Gabriel, N., Durbin‐Johnson, B., Hagerman, R. J., & Tassone, F. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36023 · Cited by 161
“CGG sizing and methylation status were assessed by Southern blot and polymerase chain reaction (PCR) analyses as previously described [Filipovic-Sadic et al., 2010; Tassone et al., 2008].”
MethodSelf-citationKaufmann, M., Schuffenhauer, A., Fruh, I., Klein, J., Thiemeyer, A., Rigo, P., Gomez-Mancilla, B., Heidinger-Millot, V., Bouwmeester, T., Schopfer, U., et al. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115588287 · Cited by 87
Grigsby, J. (2016) · The Clinical Neuropsychologist · doi:10.1080/13854046.2016.1184652 · Cited by 34
Careaga, M., Noyon, T., Basuta, K., Van de Water, J., Tassone, F., Hagerman, R. J., & Ashwood, P. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-110 · Cited by 20
Self-citationHypermobile Ehlers-Danlos syndrome (hEDS) phenotype in fragile X premutation carriers: case series
Tassanakijpanich, N., McKenzie, F. J., McLennan, Y. A., Makhoul, E., Tassone, F., Jasoliya, M. J., Romney, C., Petrasic, I. C., Napalinga, K., Buchanan, C. B., et al. (2022) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2020-107609 · Cited by 9
Self-citationWinarni, T. I., Aishworiya, R., Culpepper, H., Zafarullah, M., Mendoza, G., Wilaisakditipakorn, T. J., Likhitweerawong, N., Law, J., Hagerman, R., & Tassone, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072840 · Cited by 3
“Molecular analysis included DNA testing for the FMR1 mutations by Southern Blot and PCR carried out on genomic DNA isolated from whole blood samples [64,65].”
Self-citationLau, J. C. Y., Guilfoyle, J., Crawford, S., Johnson, G., Landau, E., Xing, J., Kumareswaran, M., Ethridge, S., Butler, M., Goldman, L., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062481 · Cited by 1
Metadata
- Authors
- Filipovic-Sadic, S., Sah, S., Chen, L., Krosting, J., Sekinger, E., Zhang, W., Hagerman, P. J., Stenzel, T. T., Hadd, A. G., Latham, G. J., & Tassone, F.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-03-01
- Volume
- 56
- Issue
- 3
- Pages
- 399-408
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2104346867
- Cited by
- 278
- References
- 26
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.